Zylo Therapeutics

Executive Summary

Zylo Therapeutics is a privately held drug delivery company based in Charleston, South Carolina, founded in 2012. The company has developed a patented platform technology called Z-pods, which enables topical sustained release of active ingredients, improves druggability of challenging compounds, and introduces a novel “Patchless Patch” concept. This technology also enhances targeting of pores and follicles, offering differentiated delivery for dermatological and cosmetic applications. By leveraging its Z-pod microcarriers, Zylo aims to overcome limitations of conventional topical formulations, such as poor penetration and short retention time, thereby expanding the therapeutic potential of both existing and novel drugs. Despite limited public information on funding, valuation, or revenue traction, Zylo’s platform has the potential to attract partnerships with pharmaceutical and consumer health companies seeking improved topical delivery. The company remains in a growth phase, likely focused on advancing its technology toward commercial validation and securing strategic collaborations. With a differentiated approach to topical drug delivery, Zylo is positioned to address unmet needs in dermatology, wound care, and aesthetics. However, given the early-stage nature and lack of disclosed milestones, conviction in near-term commercial success is moderate.

Upcoming Catalysts (preview)

• Q4 2026Partnership with a major pharmaceutical or consumer health company for Z-pod platform licensing60% success
• Q2 2027Completion of a preclinical proof-of-concept study for a lead candidate70% success
• Q3 2026Series A or Series B funding round to support platform expansion50% success